PI
ACRS icon

Putnam Investments’s Aclaris Therapeutics ACRS Stock Holding History

Putnam Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-29,162
Closed -$582K – 1064
2018
Q2 		$582K Sell
29,162
-26,947
-48% -$498K ﹤0.01% 922
2018
Q1 		$983K Sell
56,109
-585,733
-91% -$12.4M ﹤0.01% 867
2017
Q4 		$15.8M Sell
641,842
-39,977
-6% -$973K 0.04% 310
2017
Q3 		$17.6M Buy
681,819
+147,015
+27% +$3.94M 0.04% 283
2017
Q2 		$14.5M Buy
534,804
+394,536
+281% +$10.7M 0.03% 314
2017
Q1 		$4.18M Buy
+140,268
New +$4.04M 0.01% 657

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Putnam Investments's ACRS Position: Q3 2018 in Review

Putnam Investments sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 29,162 shares — an estimated $582K sold.

Putnam Investments first reported a position in ACRS in Q1 2017 and held it in 6 quarters. The position peaked at $17.6M in Q3 2017. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • Putnam Investments reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Putnam Investments sold 29,162 Aclaris Therapeutics shares in Q3 2018, an estimated $582K.
  • Putnam Investments first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 6 quarters.
  • Putnam Investments's Aclaris Therapeutics position peaked at $17.6M in Q3 2017.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on Putnam Investments's 13F filing for Q3 2018, filed 14 Nov 2018.